What is PROK's current stock price?

PROK (ProKidney Corp.) is currently trading at $1.75 with a market cap of $563.9M.

What sector is ProKidney Corp. in?

ProKidney Corp. (PROK) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PROK a good stock to buy?

Analysts have a Hold consensus on PROK with a price target of $4.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PROK ProKidney Corp.

Healthcare

$1.75+0.00%ClosedMarket Cap: $563.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-0.24

P/S

634.31

EV/EBITDA

-2.99

DCF Value

$0.88

FCF Yield

-26.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

-224.4%

Operating Margin

-18959.7%

Net Margin

-8418.0%

ROE

7.4%

ROA

-25.6%

ROIC

-54.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$226.0K	$-22.6M	$—
Q4 null	$225.0K	$-19.2M	$—
FY null	$893.0K	$-69.0M	$—
Q3 null	$217.0K	$-16.5M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$4.67

Target (Median)

$5.00

Target Range

$3.00 - $6.00

0 Strong Buy4 Buy2 Hold0 Sell1 Strong Sell

HC Wainwright & Co.Buy

2026-05-18

UBSBuy

2025-07-15

GuggenheimBuy

2025-07-14

CitigroupBuy

2025-07-09

B of A SecuritiesUnderperform

2025-06-30

Trading Activity

Insider Trades

View All

Control Empresarial de Capitales S.A. de C.V.10 percent owner, other: Add'l Rep. Persons-see Ex.99-1

SellThu Apr 30

Weber Darin J.officer: Chief Regulatory Officer

SellTue Mar 03

Girolamo Todd Cofficer: Chief Legal Officer

SellTue Mar 03

Culleton Brucedirector, officer: Chief Executive Officer

SellTue Mar 03

Coulston Jamesofficer: Chief Financial Officer

SellTue Mar 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.75

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Peers